Summary
Gilead Sciences, Inc. (GILD) has filed an 8-K report on February 11, 2025, to announce its financial results for the fourth quarter and full year ended December 31, 2024. The report primarily directs investors to an accompanying press release (Exhibit 99.1) which contains the detailed financial outcomes and management's commentary. Investors should note that Gilead provides both GAAP and non-GAAP financial measures, with management believing the non-GAAP figures offer valuable insights into operational performance for internal planning and budgeting purposes. While specific figures are not detailed within the 8-K itself, the filing indicates that the press release includes a comprehensive reconciliation between GAAP and non-GAAP financial information. This reconciliation is crucial for investors seeking to understand the nuances of Gilead's financial reporting. The information provided in this 8-K, including the press release, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, meaning it does not carry the same liability as a formally filed document.
Key Highlights
- 1Gilead Sciences (GILD) released its Q4 and full-year 2024 financial results on February 11, 2025, via an 8-K filing.
- 2The primary details of the financial results are contained within an accompanying press release (Exhibit 99.1).
- 3The company reports financial results using both U.S. GAAP and non-GAAP measures.
- 4Management considers non-GAAP financial information useful for understanding operational performance and for internal planning.
- 5A reconciliation between GAAP and non-GAAP figures is provided in the press release.
- 6The information furnished in this report is not considered "filed" under Section 18 of the Exchange Act.